This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubin, J. Articles by Rosen, C. J. Search for Related Content PubMed PubMed Citation Articles by Rubin, J. Articles by Rosen, C. J. Pubmed/NCBI databases Substance via MeSH

IGF-I Regulates Osteoprotegerin (OPG) and Receptor Activator of Nuclear Factor-B Ligand in Vitro and OPG in Vivo

Emory University and Veterans Affairs Medical Center (J.R., L.Z., X.F., T.C.M., M.S.N.), Decatur, Georgia 30033; The Jackson Laboratory (C.L.A.-B., W.G.B., C.J.R.), Bar Harbor, Maine 04609; Maine Center for Osteoporosis Research and Education (W.G.B., C.J.R.), St. Joseph Hospital, Bangor, Maine 04401; and Veterans Affairs Medical Center (R.M., L.H.), Palo Alto, California 94304

Address all correspondence and requests for reprints to: Clifford Rosen, M.D., Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor, Maine 04401. E-mail: . rofe{at}aol.com

Abstract

IGF-I, a ubiquitous polypeptide, plays a key role in longitudinal bone growth and acquisition. The most predominant effect of skeletal IGF-I is acceleration of the differentiation program for osteoblasts. However, in vivo studies using recombinant human (rh) IGF-I and/or rhGH have demonstrated stimulation of both bone formation and resorption, thereby potentially limiting the usefulness of these peptides in the treatment of osteoporosis. In this study, we hypothesized that IGF-I modulates bone resorption by regulating expression of osteoprotegerin (OPG) and receptor activator of nuclear factor-B (RANK) ligand (RANKL) in bone cells. Using Northern analysis in ST2 cells, we found that human IGF-I suppressed OPG mRNA in a time- and dose-dependent manner: 100 µg/LIGF-I (13 nM) decreased OPG expression by 37.0 ± 1.8% (P < 0.002). The half maximal inhibitory dose of IGF-I was reached at 50 µg/liter (6.5 nM) with no effect of IGF-I on OPG message stability. Conditioned media from ST2 cells confirmed that IGF-I decreased secreted OPG, reducing levels by 42%, from 12.1–7 ng/ml at 48 h (P < 0.05). Similarly, IGF-I at 100 µg/liter (13 nM) increased RANKL mRNA expression to 353 ± 74% above untreated cells as assessed by real-time PCR. In vivo, low doses of rhGH when administered to elderly postmenopausal women only modestly raised serum IGF-I (to concentrations of 18–26 nM) and did not affect circulating OPG concentrations; however, administration of rhIGF-I (30 µg/kg•d) for 1 yr to older women resulted in a significant increase in serum IGF-I (to concentrations of 39–45 nM) and a 20% reduction in serum OPG (P < 0.05). In summary, we conclude that IGF-I in a dose- and time-dependent manner regulates OPG and RANKL in vitro and in vivo. These data suggest IGF-I may act as a coupling factor in bone remodeling by activating both bone formation and bone resorption; the latter effect appears to be mediated through the OPG/RANKL system in bone.

This article has been cited by other articles:

				A. D Anastasilakis, D. G Goulis, S. A Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, and A. Avramidis Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide Eur. J. Endocrinol., March 1, 2008; 158(3): 411 - 415. [Abstract] [Full Text] [PDF]

				E Mrak, I Villa, R Lanzi, M Losa, F Guidobono, and A Rubinacci Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells J. Endocrinol., March 1, 2007; 192(3): 639 - 645. [Abstract] [Full Text] [PDF]

				K. M. Delahunty, K. L. Shultz, G. A. Gronowicz, B. Koczon-Jaremko, M. L. Adamo, L. G. Horton, J. Lorenzo, L. R. Donahue, C. Ackert-Bicknell, B. E. Kream, et al. Congenic Mice Provide in Vivo Evidence for a Genetic Locus that Modulates Serum Insulin-Like Growth Factor-I and Bone Acquisition Endocrinology, August 1, 2006; 147(8): 3915 - 3923. [Abstract] [Full Text] [PDF]

				C. M. van Golen, T. S. Schwab, B. Kim, M. E. Soules, S. Su Oh, K. Fung, K. L. van Golen, and E. L. Feldman Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone. Cancer Res., July 1, 2006; 66(13): 6570 - 6578. [Abstract] [Full Text] [PDF]

				S. Yakar, M. L Bouxsein, E. Canalis, H. Sun, V. Glatt, C. Gundberg, P. Cohen, D. Hwang, Y. Boisclair, D. LeRoith, et al. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J. Endocrinol., May 1, 2006; 189(2): 289 - 299. [Abstract] [Full Text] [PDF]

				L. M. Rasmussen, L. Tarnow, T. K. Hansen, H.-H. Parving, and A. Flyvbjerg Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients Eur. J. Endocrinol., January 1, 2006; 154(1): 75 - 81. [Abstract] [Full Text] [PDF]

				J. Jadlowiec, D. Dongell, J. Smith, C. Conover, and P. Campbell Pregnancy-Associated Plasma Protein-A Is Involved in Matrix Mineralization of Human Adult Mesenchymal Stem Cells and Angiogenesis in the Chick Chorioallontoic Membrane Endocrinology, September 1, 2005; 146(9): 3765 - 3772. [Abstract] [Full Text] [PDF]

				F. Y.-I. Lee, D.-W. Kim, J. A. Karmin, D. Hong, S.-S. Chang, M. Fujisawa, H. Takayanagi, L. U. Bigliani, T. A. Blaine, and H.-J. Lee {micro}-Calpain Regulates Receptor Activator of NF-{kappa}B Ligand (RANKL)-supported Osteoclastogenesis via NF-{kappa}B Activation in RAW 264.7 Cells J. Biol. Chem., August 19, 2005; 280(33): 29929 - 29936. [Abstract] [Full Text] [PDF]

				M. G. Choi, H. S. Koh, D. Kluess, D. O'Connor, A. Mathur, G. A. Truskey, J. Rubin, D. X. F. Zhou, and K.-L. P. Sung Effects of titanium particle size on osteoblast functions in vitro and in vivo PNAS, March 22, 2005; 102(12): 4578 - 4583. [Abstract] [Full Text] [PDF]

				T. Ueland GH/IGF-I and bone resorption in vivo and in vitro Eur. J. Endocrinol., March 1, 2005; 152(3): 327 - 332. [Abstract] [Full Text] [PDF]

				U. H. Lerner NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION Crit. Rev. Oral. Biol. Med., March 1, 2004; 15(2): 64 - 81. [Abstract] [Full Text]

				X. Fan, E. Roy, L. Zhu, T. C. Murphy, C. Ackert-Bicknell, C. M. Hart, C. Rosen, M. S. Nanes, and J. Rubin Nitric Oxide Regulates Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin Expression in Bone Marrow Stromal Cells Endocrinology, February 1, 2004; 145(2): 751 - 759. [Abstract] [Full Text] [PDF]

				C. Parkinson, M. Kassem, L. Heickendorff, A. Flyvbjerg, and P. J. Trainer Pegvisomant-Induced Serum Insulin-Like Growth Factor-I Normalization in Patients with Acromegaly Returns Elevated Markers of Bone Turnover to Normal J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5650 - 5655. [Abstract] [Full Text] [PDF]

				C. J. Rosen Insulin-Like Growth Factor I and Calcium Balance: Evolving Concepts of an Evolutionary Process Endocrinology, November 1, 2003; 144(11): 4679 - 4681. [Full Text] [PDF]

				J. Rubin, T. C. Murphy, L. Zhu, E. Roy, M. S. Nanes, and X. Fan Mechanical Strain Differentially Regulates Endothelial Nitric-oxide Synthase and Receptor Activator of Nuclear {kappa}B Ligand Expression via ERK1/2 MAPK J. Biol. Chem., September 5, 2003; 278(36): 34018 - 34025. [Abstract] [Full Text] [PDF]

				M. Misra, L. A. Soyka, K. K. Miller, D. B. Herzog, S. Grinspoon, D. de Chen, G. Neubauer, and A. Klibanski Serum Osteoprotegerin in Adolescent Girls with Anorexia Nervosa J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3816 - 3822. [Abstract] [Full Text] [PDF]

				S. Yakar and C. J. Rosen From Mouse to Man: Redefining the Role of Insulin-Like Growth Factor-I in the Acquisition of Bone Mass Experimental Biology and Medicine, March 1, 2003; 228(3): 245 - 252. [Abstract] [Full Text] [PDF]